No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients

被引：17
|
作者：
Schippers, EF
Hugen, PWH
den Hartigh, J
Burger, DM
Hoetelmans, RMW
Visser, LG
Kroon, FP
机构：
[1] Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands
[3] Univ Nijmegen, Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
[4] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
来源：
AIDS | 2000年 / 14卷 / 17期
关键词：
D O I：
10.1097/00002030-200012010-00023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：2794 / 2795
页数：2
相关论文
共 50 条
  • [1] Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals
    Burger, D
    Hugen, P
    Reiss, P
    Gyssens, I
    Schneider, M
    Kroon, F
    Schreij, G
    Brinkman, K
    Richter, C
    Prins, J
    Aarnoutse, R
    Lange, J
    AIDS, 2003, 17 (08) : 1157 - 1165
  • [2] Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women
    Kosel, BW
    Beckerman, KP
    Hayashi, S
    Homma, M
    Aweeka, FT
    AIDS, 2003, 17 (08) : 1195 - 1199
  • [3] Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis
    Crommentuyn, KML
    Mulder, JW
    Sparidans, RW
    Huitema, ADR
    Schellens, JHM
    Beijnen, JH
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (08) : E73 - E75
  • [4] Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children
    Bergshoeff, AS
    Fraaij, PL
    Ndagijimana, J
    Verweel, G
    Hartwig, NG
    Niehues, T
    De Groot, R
    Burger, DM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (01) : 63 - 68
  • [5] Indinavir in cerebrospinal fluid of HIV-1-infected patients
    Ståhle, L
    Martin, C
    Svensson, JO
    Sönnerborg, A
    LANCET, 1997, 350 (9094): : 1823 - 1823
  • [6] Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir
    Yerly, S
    Rickenbach, M
    Popescu, M
    Taffe, P
    Craig, C
    Perrin, L
    ANTIVIRAL THERAPY, 2001, 6 (03) : 185 - 189
  • [7] Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individuals
    de Maat, MM
    Huitema, ADR
    Mulder, JW
    Meenhorst, PL
    van Gorp, ECM
    Mairuhu, ATA
    Beijnen, JH
    CLINICAL DRUG INVESTIGATION, 2003, 23 (10) : 629 - 637
  • [8] Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals
    Monique M. R. de Maat
    Alwin D. R. Huitema
    Jan W. Mulder
    Pieter L. Meenhorst
    Eric C. M. van Gorp
    Albert T. A. Mairuhu
    Jos H. Beijnen
    Clinical Drug Investigation, 2003, 23 : 629 - 637
  • [9] The pharmacokinetics of nelfinavir in HIV-1-infected children
    van Heeswijk, RPG
    Scherpbier, HJ
    de Koning, LA
    Heymans, HSA
    Lange, JMA
    Beijnen, JH
    Hoetelmans, RMW
    THERAPEUTIC DRUG MONITORING, 2002, 24 (04) : 487 - 491
  • [10] Antiretroviral Drug-Drug Interaction Considerations for HIV-Infected Children
    Fletcher, Courtney V.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (05) : 429 - 430
12345